|
1
|
Mungall AJ, Palmer SA, Sims SK, Edwards
CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE,
et al: The DNA sequence and analysis of human chromosome 6. Nature.
425:805–811. 2003.
|
|
2
|
Robinson J, Barker DJ, Georgiou X, Cooper
MA, Flicek P and Marsh SGE: IPD-IMGT/HLA Database. Nucleic Acids
Res. 48(D1): D948–D955. 2020.
|
|
3
|
Urban RG, Chicz RM and Hedley ML: The
discovery and use of HLA-associated epitopes as drugs. Crit Rev
Immunol. 17:387–397. 1997.
|
|
4
|
Blees A, Januliene D, Hofmann T, Koller N,
Schmidt C, Trowitzsch S, Moeller A and Tampé R: Structure of the
human MHC-I peptide-loading complex. Nature. 551:525–528. 2017.
|
|
5
|
Reith W, LeibundGut-Landmann S and
Waldburger JM: Regulation of MHC class II gene expression by the
class II transactivator. Nat Rev Immunol. 5:793–806. 2005.
|
|
6
|
Boegel S, Löwer M, Bukur T, Sorn P, Castle
JC and Sahin U: HLA and proteasome expression body map. BMC Med
Genomics. 11:362018.
|
|
7
|
Liu B, Shao Y and Fu R: Current research
status of HLA in immune-related diseases. Immun Inflamm Dis.
9:340–350. 2021.
|
|
8
|
Blum JS, Wearsch PA and Cresswell P:
Pathways of antigen processing. Annu Rev Immunol. 31:443–473.
2013.
|
|
9
|
Hazini A, Fisher K and Seymour L:
Deregulation of HLA-I in cancer and its central importance for
immunotherapy. J Immunother Cancer. 9:e0028992021.
|
|
10
|
Marcu A, Bichmann L, Kuchenbecker L,
Kowalewski DJ, Freudenmann LK, Backert L, Mühlenbruch L, Szolek A,
Lübke M, Wagner P, et al: HLA Ligand Atlas: A benign reference of
HLA-presented peptides to improve T-cell-based cancer
immunotherapy. J Immunother Cancer. 9:e0020712021.
|
|
11
|
Djajadiningrat RS, Horenblas S, Heideman
DA, Sanders J, de Jong J and Jordanova ES: Classic and nonclassic
HLA class I expression in penile cancer and relation to HPV status
and clinical outcome. J Urol. 193:1245–1251. 2015.
|
|
12
|
Cruz FM, Chan A and Rock KL: Pathways of
MHC I cross-presentation of exogenous antigens. Semin Immunol.
66:1017292023.
|
|
13
|
Bradley P: Structure-based prediction of T
cell receptor:peptide-MHC interactions. Elife. 12:e828132023.
|
|
14
|
Sarri CA, Giannoulis T, Moutou KA and
Mamuris Z: HLA class II peptide-binding-region analysis reveals
funneling of polymorphism in action. Immunol Lett. 238:75–95.
2021.
|
|
15
|
Klein J and Sato A: The HLA system. First
of two parts. N Engl J Med. 343:702–709. 2000.
|
|
16
|
Mišunová M, Svitálková T, Pleštilová L,
Kryštufková O, Tegzová D, Svobodová R, Hušáková M, Tomčík M, Bečvář
R, Závada J, et al: Molecular markers of systemic autoimmune
disorders: The expression of MHC-located HSP70 genes is
significantly associated with autoimmunity development. Clin Exp
Rheumatol. 35:33–42. 2017.
|
|
17
|
Ota M, Katsuyama Y, Kimura A, Tsuchiya K,
Kondo M, Naruse T, Mizuki N, Itoh K, Sasazuki T and Inoko H: A
second susceptibility gene for developing rheumatoid arthritis in
the human MHC is localized within a 70-kb interval telomeric of the
TNF genes in the HLA class III region. Genomics. 71:263–270.
2001.
|
|
18
|
Cucca F, Zhu ZB, Khanna A, Cossu F, Congia
M, Badiali M, Lampis R, Frau F, De Virgiliis S, Cao A, et al:
Evaluation of IgA deficiency in Sardinians indicates a
susceptibility gene is encoded within the HLA class III region.
Clin Exp Immunol. 111:76–80. 1998.
|
|
19
|
Arnaiz-Villena A, Suarez-Trujillo F,
Juarez I, Rodríguez-Sainz C, Palacio-Gruber J, Vaquero-Yuste C,
Molina-Alejandre M, Fernández-Cruz E and Martin-Villa JM: Evolution
and molecular interactions of major histocompatibility complex
(MHC)-G, -E and -F genes. Cell Mol Life Sci. 79:4642022.
|
|
20
|
Gulati R, Kavadichanda GC, Mariaselvam CM,
Kumar G and Negi VS: Association of HLA-G, HLA-E and HLA-B*27 with
susceptibility and clinical phenotype of enthesitis related
arthritis (ERA). Hum Immunol. 82:615–620. 2021.
|
|
21
|
Xu X, Zhou Y and Wei H: Roles of HLA-G in
the maternal-fetal immune microenvironment. Front Immunol.
11:5920102020.
|
|
22
|
Rajagopalan S and Long EO: A Human
Histocompatibility Leukocyte Antigen (HLA)-G-Specific receptor
expressed on all natural killer cells. J Exp Med. 189:1093–1100.
1999.
|
|
23
|
Mosaferi E, Alizadeh Gharamaleki N,
Farzadi L, Majidi J, Babaloo Z, Kazemi T, Ramezani M, Tabatabaei M,
Ahmadi H, Aghebati Maleki L and Baradaran B: The Study of HLA-G
gene and protein expression in patients with recurrent miscarriage.
Adv Pharm Bull. 9:70–75. 2019.
|
|
24
|
Zhuang B, Shang J and Yao Y: HLA-G: An
important mediator of maternal-fetal immune-tolerance. Front
Immunol. 12:7443242021.
|
|
25
|
Camilli G, Cassotta A, Battella S,
Palmieri G, Santoni A, Paladini F, Fiorillo MT and Sorrentino R:
Regulation and trafficking of the HLA-E molecules during
monocyte-macrophage differentiation. J Leukoc Biol. 99:121–130.
2016.
|
|
26
|
Ruibal P, Franken KLMC, van Meijgaarden
KE, Walters LC, McMichael AJ, Gillespie GM, Joosten SA and
Ottenhoff THM: Discovery of HLA-E-Presented Epitopes: MHC-E/Peptide
Binding and T-Cell Recognition. Methods Mol Biol. 2574:15–30.
2022.
|
|
27
|
Lo Monaco E, Sibilio L, Melucci E,
Tremante E, Suchànek M, Horejsi V, Martayan A and Giacomini P:
HLA-E: Strong association with beta2-microglobulin and surface
expression in the absence of HLA class I signal sequence-derived
peptides. J Immunol. 181:5442–5450. 2008.
|
|
28
|
Prašnikar E, Perdih A and Borišek J: What
a difference an amino acid makes: An All-Atom simulation study of
nonameric peptides in inhibitory HLA-E/NKG2A/CD94 immune complexes.
Front Pharmacol. 13:9254272022.
|
|
29
|
Li D, Brackenridge S, Walters LC, Swanson
O, Harlos K, Rozbesky D, Cain DW, Wiehe K, Scearce RM, Barr M, et
al: Mouse and human antibodies bind HLA-E-leader peptide complexes
and enhance NK cell cytotoxicity. Commun Biol. 5:2712022.
|
|
30
|
Morandi F, Rizzo R, Fainardi E,
Rouas-Freiss N and Pistoia V: Recent advances in our understanding
of HLA-G Biology: Lessons from a wide spectrum of human diseases. J
Immunol Res. 2016:43264952016.
|
|
31
|
Bertol BC, Dias FC, da Silva DM, Zambelli
Ramalho LN and Donadi EA: Human Antigen Leucocyte (HLA)-G and HLA-E
are differentially expressed in pancreatic disorders. Hum Immunol.
80:948–954. 2019.
|
|
32
|
Seliger B: The non-classical antigens of
HLA-G and HLA-E as diagnostic and prognostic biomarkers and as
therapeutic targets in transplantation and tumors. Clin Transpl.
465–472. 2013.
|
|
33
|
Pagliuca S, Gurnari C, Rubio MT, Visconte
V and Lenz TL: Individual HLA heterogeneity and its implications
for cellular immune evasion in cancer and beyond. Front Immunol.
13:9448722022.
|
|
34
|
Rognan D, Krebs S, Kuonen O, Lamas JR,
López de Castro JA and Folkers G: Fine specificity of antigen
binding to two class I major histocompatibility proteins (B*2705
and B*2703) differing in a single amino acid residue. J Comput
Aided Mol Des. 11:463–478. 1997.
|
|
35
|
Schendel DJ, Reinhardt C, Nelson PJ, Maget
B, Pullen L, Bornkamm GW and Steinle A: Cytotoxic T lymphocytes
show HLA-C-restricted recognition of EBV-bearing cells and
allorecognition of HLA class I molecules presenting self-peptides.
J Immunol. 149:2406–2414. 1992.
|
|
36
|
Neefjes J, Jongsma ML, Paul P and Bakke O:
Towards a systems understanding of MHC class I and MHC class II
antigen presentation. Nat Rev Immunol. 11:823–836. 2011.
|
|
37
|
Rastogi I, Jeon D, Moseman JE, Muralidhar
A, Potluri HK and McNeel DG: Role of B cells as antigen presenting
cells. Front Immunol. 13:9549362022.
|
|
38
|
Erb P, Feldmann M and Hogg N: Role of
macrophages in the generation of T helper cells. IV. Nature of
genetically related factor derived from macrophages incubated with
soluble antigens. Eur J Immunol. 6:365–372. 1976.
|
|
39
|
Erb P and Feldmann M: The role of
macrophages in the generation of T-helper cells. II. The genetic
control of the macrophage-T-cell interaction for helper cell
induction with soluble antigens. J Exp Med. 142:460–472. 1975.
|
|
40
|
Takeuchi C, Ohto H, Miura S, Yasuda H, Ono
S and Ogata T: Delayed and acute hemolytic transfusion reactions
resulting from red cell antibodies and red cell-reactive HLA
antibodies. Transfusion. 45:1925–1929. 2005.
|
|
41
|
Chen Y, Huang XJ, Wang Y, Liu KY, Chen H,
Chen YH, Zhang XH, Wang FR, Han W, Wang JZ, et al: Febrile reaction
associated with the infusion of haploidentical peripheral blood
stem cells: Incidence, clinical features, and risk factors.
Transfusion. 55:2023–2031. 2015.
|
|
42
|
Gavroy B, Timmermans T, Van Caenegem O,
Mastrobuoni S, Jacquet L, Latinne D and Poncelet AJ: Significance
of HLA-matching and anti-HLA antibodies in heart transplant
patients receiving induction therapy? Transpl Immunol.
75:1017062022.
|
|
43
|
Rennie TJW, Battle RK, Abel AA, McConnell
S, McLaren R, Phelan PJ, Geddes C, Padmanabhan N, Clancy MJ, Little
AM and Turner DM: Comparison of kidney transplant outcomes in HLA
compatible and incompatible transplantation: A national cohort
study. Nephrology (Carlton). 27:962–972. 2022.
|
|
44
|
Chen R, Yi H, Zhen J, Fan M, Xiao L, Yu Q,
Yang Z, Ning L, Deng Z and Chen G: Donor with HLA-C2 is associated
with acute rejection following liver transplantation in Southern
Chinese. HLA. 100:133–141. 2022.
|
|
45
|
Kim HE, Yang YH, Paik HC, Jeong SJ, Kim
SY, Park MS and Lee JG: The Assessment and outcomes of
crossmatching in lung transplantation in Korean patients. J Korean
Med Sci. 37:e1772022.
|
|
46
|
Halleck F, Khadzhynov D, Liefeldt L,
Schrezenmeier E, Lehner L, Duerr M, Schmidt D, Bamoulid J, Lachmann
N, Waiser J, et al: Immunologic outcome in elderly kidney
transplant recipients: Is it time for HLA-DR matching? Nephrol Dial
Transplant. 31:2143–2149. 2016.
|
|
47
|
Arcuri LJ, Kerbauy MN, Kerbauy LN, Santos
FPS, Ribeiro AAF and Hamerschlak N: ATG in HLA-matched, peripheral
blood, hematopoietic cell transplantation in acute myeloid leukemia
and myelodysplastic syndrome: A secondary analysis of a CIBMTR
database. Transplant Cell Ther. 29:40.e1–40.e4. 2023.
|
|
48
|
Steens J and Klein D: HOX genes in stem
cells: Maintaining cellular identity and regulation of
differentiation. Front Cell Dev Biol. 10:10029092022.
|
|
49
|
Olerup O, Möller E and Persson U: HLA-DP
incompatibilities induce significant proliferation in primary mixed
lymphocyte cultures in HLA-A, -B, -DR and -DQ compatible
individuals: Implications for allogeneic bone marrow
transplantation. Tissue Antigens. 36:194–202. 1990.
|
|
50
|
Jin DQ and Zheng XF: HLA gene polymorphism
and forensic medicine. Fa Yi Xue Za Zhi. 19:51–53. 2003.In
Chinese.
|
|
51
|
Ritzmann SE: HLA patterns and disease
associations. JAMA. 236:2305–2309. 1976.
|
|
52
|
Hanson A and Brown MA: Genetics and the
causes of ankylosing spondylitis. Rheum Dis Clin North Am.
43:401–414. 2017.
|
|
53
|
Abdou AM, Gao X, Cozen W, Cerhan JR,
Rothman N, Martin MP, Davis S, Schenk M, Chanock SJ, Hartge P, et
al: Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor
necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma.
Leukemia. 24:1055–1058. 2010.
|
|
54
|
Baxter KR and Opremcak EM: Panretinal
acute multifocal placoid pigment epitheliopathy: A novel posterior
uveitis syndrome with HLA-A3 and HLA-C7 association. J Ophthalmic
Inflamm Infect. 3:292013.
|
|
55
|
Mohammad-Ebrahim H, Kamali-Sarvestani E,
Mahmoudi M, Beigy M, Karami J, Ahmadzadeh N and Shahram F:
Association of killer cell immunoglobulin-like receptor (KIR) genes
and their HLA ligands with susceptibility to Behçet's disease.
Scand J Rheumatol. 47:155–163. 2018.
|
|
56
|
López-Vázquez A, Rodrigo L and
López-Larrea C: Association of killer immunoglobulin-like receptors
and their HLA Class I ligands with progression of chronic hepatitis
C virus infection. Tissue Antigens. 69(Suppl 1): S241–S242.
2007.
|
|
57
|
Golubovic G, Stajic M, Stolic I, Nikolic
JA, Neskovic AN and Pandey L: Histocompatibility antigens in
patients with hepatocellular carcinoma. Z Gastroenterol. 34:15–20.
1996.
|
|
58
|
Ricci G, Colombo C, Ghiazza B, Porta C,
Moroni M and Illeni MT: HLA-A, B, C, DR and DQ expression and
hepatocellular carcinoma: Study of 205 Italian subjects. Cancer
Lett. 98:121–125. 1995.
|
|
59
|
El-Chennawi FA, Auf FA, Metwally SS,
Mosaad YM, El-Wahab MA and Tawhid ZE: HLA-class II alleles in
Egyptian patients with hepatocellular carcinoma. Immunol Invest.
37:661–674. 2008.
|
|
60
|
De Re V, Caggiari L, Talamini R, Crovatto
M, De Vita S, Mazzaro C, Cannizzaro R, Dolcetti R and Boiocchi M:
Hepatitis C virus-related hepatocellular carcinoma and B-cell
lymphoma patients show a different profile of major
histocompatibility complex class II alleles. Hum Immunol.
65:1397–1404. 2004.
|
|
61
|
Gamzatova Z, Villabona L, van der Zanden
H, Haasnoot GW, Andersson E, Kiessling R, Seliger B, Kanter L,
Dalianis T, Bergfeldt K and Masucci GV: Analysis of HLA class I-II
haplotype frequency and segregation in a cohort of patients with
advanced stage ovarian cancer. Tissue Antigens. 70:205–213.
2007.
|
|
62
|
Kübler K, Arndt PF, Wardelmann E, Krebs D,
Kuhn W and van der Ven K: HLA-class II haplotype associations with
ovarian cancer. Int J Cancer. 119:2980–2985. 2006.
|
|
63
|
Yang YC, Chang TY, Lee YJ, Su TH, Dang CW,
Wu CC, Liu HF, Chu CC and Lin M: HLA-DRB1 alleles and cervical
squamous cell carcinoma: Experimental study and meta-analysis. Hum
Immunol. 67:331–340. 2006.
|
|
64
|
Schiff MA, Apple RJ, Lin P, Nelson JL,
Wheeler CM and Becker TM: HLA alleles and risk of cervical
intraepithelial neoplasia among Southwestern American Indian women.
Hum Immunol. 66:1050–1056. 2005.
|
|
65
|
Guerini FR, Agliardi C, Zanzottera M,
Delbue S, Pagani E, Tinelli C, Boldorini R, Car PG, Veggiani C and
Ferrante P: Human leukocyte antigen distribution analysis in North
Italian brain Glioma patients: An association with HLA-DRB1*14. J
Neurooncol. 77:213–217. 2006.
|
|
66
|
Masala MV, Carcassi C, Cottoni F, Mulargia
M, Contu L and Cerimele D: Classic Kaposi's sarcoma in Sardinia HLA
positive and negative associations. Int J Dermatol. 44:743–745.
2005.
|
|
67
|
Reinders J, Rozemuller EH, Otten HG, van
der Veken LT, Slootweg PJ and Tilanus MG: HLA and MICA associations
with head and neck squamous cell carcinoma. Oral Oncol. 43:232–240.
2007.
|
|
68
|
He X, Dong DD, Yie SM, Yang H, Cao M, Ye
SR, Li K, Liu J and Chen J: HLA-G expression in human breast
cancer: Implications for diagnosis and prognosis, and effect on
allocytotoxic lymphocyte response after hormone treatment in vitro.
Ann Surg Oncol. 17:1459–1469. 2010.
|
|
69
|
Zidi I, Kharrat N, Sebai R, Zidi N, Ben
Yahia H, Bouaziz A, Rifi H, Mezlini A and Rizzo R: Pregnancy and
breastfeeding: A new theory for sHLA-G in breast cancer patients?
Immunol Res. 64:636–639. 2016.
|
|
70
|
Jung YW, Kim YT, Kim SW, Kim S, Kim JH,
Cho NH and Kim JW: Correlation of human leukocyte antigen-G (HLA-G)
expression and disease progression in epithelial ovarian cancer.
Reprod Sci. 16:1103–1111. 2013.
|
|
71
|
Lin A, Zhu CC, Chen HX, Chen BF, Zhang X,
Zhang JG, Wang Q, Zhou WJ, Hu W, Yang HH, et al: Clinical relevance
and functional implications for human leukocyte antigen-g
expression in non-small-cell lung cancer. J Cell Mol Med.
14:2318–2329. 2010.
|
|
72
|
Tronik-Le Roux D, Renard J, Vérine J,
Renault V, Tubacher E, LeMaoult J, Rouas-Freiss N, Deleuze JF,
Desgrandschamps F and Carosella ED: Novel landscape of HLA-G
isoforms expressed in clear cell renal cell carcinoma patients. Mol
Oncol. 11:1561–1578. 2017.
|
|
73
|
Zheng J, Xu C, Chu D, Zhang X, Li J, Ji G,
Hong L, Feng Q, Li X, Wu G, et al: Human leukocyte antigen G is
associated with esophageal squamous cell carcinoma progression and
poor prognosis. Immunol Lett. 161:13–19. 2014.
|
|
74
|
Catamo E, Zupin L, Crovella S, Celsi F and
Segat L: Non-classical MHC-I human leukocyte antigen (HLA-G) in
hepatotropic viral infections and in hepatocellular carcinoma. Hum
Immunol. 75:1225–1231. 2014.
|
|
75
|
Kaprio T, Sariola H, Linder N, Lundin J,
Kere J, Haglund C and Wedenoja S: HLA-G expression correlates with
histological grade but not with prognosis in colorectal carcinoma.
HLA. 98:213–217. 2021.
|
|
76
|
Jiao F, Zhou J, Sun H, Song X and Song Y:
Plasma soluble human leukocyte antigen G predicts the long-term
prognosis in patients with colorectal cancer. Transl Cancer Res.
9:4011–4019. 2020.
|
|
77
|
Cao M, Yie SM, Liu J, Ye SR, Xia D and Gao
E: Plasma soluble HLA-G is a potential biomarker for diagnosis of
colorectal, gastric, esophageal and lung cancer. Tissue Antigens.
78:120–128. 2011.
|
|
78
|
Ferguson R, Ramanakumar AV, Richardson H,
Tellier PP, Coutlée F, Franco EL and Roger M: Human leukocyte
antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus
infection susceptibility and persistence. Hum Immunol. 72:337–341.
2011.
|
|
79
|
Dutta N, Majumder D, Gupta A, Mazumder DN
and Banerjee S: Analysis of human lymphocyte antigen class I
expression in gastric cancer by reverse transcriptase-polymerase
chain reaction. Hum Immunol. 66:164–169. 2005.
|
|
80
|
Chen A, Shen Y, Xia M, Xu L, Pan N, Yin Y,
Miao F, Shen C, Xie W and Zhang J: Expression of the nonclassical
HLA class I and MICA/B molecules in human hepatocellular carcinoma.
Neoplasma. 58:371–376. 2011.
|
|
81
|
Zhou Y, Wu Z, Tang Y and Jia T: HLA-E gene
polymorphisms and plasma soluble HLA-E levels and their
relationship with genetic susceptibility to breast cancer. Xi Bao
Yu Fen Zi Mian Yi Xue Za Zhi. 31:524–527. 2015.In Chinese.
|
|
82
|
Mouchess ML and Anderson M: Central
tolerance induction. Curr Top Microbiol Immunol. 373:69–86.
2014.
|
|
83
|
Goulmy E, Termijtelen A, Bradley BA and
van Rood JJ: Y-antigen killing by T cells of women is restricted by
HLA. Nature. 266:544–545. 1977.
|
|
84
|
Dersh D, Hollý J and Yewdell JW: A few
good peptides: MHC class I-based cancer immunosurveillance and
immunoevasion. Nat Rev Immunol. 21:116–128. 2021.
|
|
85
|
Ryschich E, Nötzel T, Hinz U, Autschbach
F, Ferguson J, Simon I, Weitz J, Fröhlich B, Klar E, Büchler MW and
Schmidt J: Control of T-cell-mediated immune response by HLA class
I in human pancreatic carcinoma. Clin Cancer Res. 11(2 Pt 1):
498–504. 2005.
|
|
86
|
Yang W, Li Y, Gao R, Xiu Z and Sun T: MHC
class I dysfunction of glioma stem cells escapes from CTL-mediated
immune response via activation of Wnt/β-catenin signaling pathway.
Oncogene. 39:1098–1111. 2020.
|
|
87
|
Burr ML, Sparbier CE, Chan KL, Chan YC,
Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC,
Gilan O, et al: An evolutionarily conserved function of polycomb
silences the MHC class I antigen presentation pathway and enables
immune evasion in cancer. Cancer Cell. 36:385–401.e8. 2019.
|
|
88
|
Chew GL, Campbell AE, De Neef E, Sutliff
NA, Shadle SC, Tapscott SJ and Bradley RK: DUX4 suppresses MHC
class I to promote cancer immune evasion and resistance to
checkpoint blockade. Dev Cell. 50:658–671.e7. 2019.
|
|
89
|
Zebertavage LK, Alice A, Crittenden MR and
Gough MJ: Transcriptional upregulation of NLRC5 by radiation drives
STING- and interferon-independent MHC-I expression on cancer cells
and T cell cytotoxicity. Sci Rep. 10:73762020.
|
|
90
|
Björkström NK, Strunz B and Ljunggren HG:
Natural killer cells in antiviral immunity. Nat Rev Immunol.
22:112–123. 2022.
|
|
91
|
Höglund P and Brodin P: Current
perspectives of natural killer cell education by MHC class I
molecules. Nat Rev Immunol. 10:724–734. 2010.
|
|
92
|
Wolf NK, Kissiov DU and Raulet DH: Roles
of natural killer cells in immunity to cancer, and applications to
immunotherapy. Nat Rev Immunol. 23:90–105. 2023.
|
|
93
|
Ferrari de Andrade L, Tay RE, Pan D, Luoma
AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ,
et al: Antibody-mediated inhibition of MICA and MICB shedding
promotes NK cell-driven tumor immunity. Science. 359:1537–1542.
2018.
|
|
94
|
Jarduli LR, Sell AM, Reis PG, Sippert EÂ,
Ayo CM, Mazini PS, Alves HV, Teixeira JJ and Visentainer JE: Role
of HLA, KIR, MICA, and cytokines genes in leprosy. Biomed Res Int.
2013:9898372013.
|
|
95
|
Chen D and Gyllensten U: MICA
polymorphism: Biology and importance in cancer. Carcinogenesis.
35:2633–2642. 2014.
|
|
96
|
Lo SS, Lee YJ, Wu CW, Liu CJ, Huang JW and
Lui WY: The increase of MICA gene A9 allele associated with gastric
cancer and less schirrous change. Br J Cancer. 90:1809–1813.
2004.
|
|
97
|
Chung-Ji L, Yann-Jinn L, Hsin-Fu L,
Ching-Wen D, Che-Shoa C, Yi-Shing L and Kuo-Wei C: The increase in
the frequency of MICA gene A6 allele in oral squamous cell
carcinoma. J Oral Pathol Med. 31:323–328. 2002.
|
|
98
|
Moretta L, Bottino C, Cantoni C, Mingari
MC and Moretta A: Human natural killer cell function and receptors.
Curr Opin Pharmacol. 1:387–391. 2001.
|
|
99
|
Moretta A, Parolini S, Castriconi R,
Bottino C, Vitale M, Sivori S and Millo R: Function and specificity
of human natural killer cell receptors. Eur J Immunogenet.
24:455–468. 1997.
|
|
100
|
Wu J, Song Y, Bakker AB, Bauer S, Spies T,
Lanier LL and Phillips JH: An activating immunoreceptor complex
formed by NKG2D and DAP10. Science. 285:730–732. 1999.
|
|
101
|
Danier AC, de Melo RP, Napimoga MH and
Laguna-Abreu MT: The role of natural killer cells in chronic
myeloid leukemia. Rev Bras Hematol Hemoter. 33:216–220. 2011.
|
|
102
|
Nwangwu CA, Weiher H and Schmidt-Wolf IGH:
Increase of CIK cell efficacy by upregulating cell surface MICA and
inhibition of NKG2D ligand shedding in multiple myeloma. Hematol
Oncol. 35:719–725. 2017.
|
|
103
|
Zhang C, Tian ZG, Zhang J, Feng JB, Zhang
JH and Xu XQ: The negative regulatory effect of IFN-gamma on
cognitive function of human natural killer cells. Zhonghua Zhong
Liu Za Zhi. 26:324–327. 2004.In Chinese.
|
|
104
|
Kuroda H, Saito H and Ikeguchi M:
Decreased number and reduced NKG2D expression of Vδ1 γδ T cells are
involved in the impaired function of Vδ1 γδ T cells in the tissue
of gastric cancer. Gastric Cancer. 15:433–439. 2012.
|
|
105
|
Qi J, Peng P, Dai MH, Li YH, Cui LX and He
W: Cytotoxicity of MICA-reactive V delta 1 gamma delta T cells
towards epithelial tumor cells. Zhongguo Yi Xue Ke Xue Yuan Xue
Bao. 26:1–7. 2004.In Chinese.
|
|
106
|
Lv D, Khawar MB, Liang Z, Gao Y and Sun H:
Neoantigens and NK Cells: 'Trick or Treat' the Cancers? Front
Immunol. 13:9318622022.
|
|
107
|
Bertolino P and Rabourdin-Combe C: The MHC
class II-associated invariant chain: A molecule with multiple roles
in MHC class II biosynthesis and antigen presentation to CD4+ T
cells. Crit Rev Immunol. 16:359–379. 1996.
|
|
108
|
Qian J, Luo F, Yang J, Liu J, Liu R, Wang
L, Wang C, Deng Y, Lu Z, Wang Y, et al: TLR2 promotes glioma immune
evasion by downregulating MHC class II molecules in microglia.
Cancer Immunol Res. 6:1220–1233. 2018.
|
|
109
|
Tarafdar A, Hopcroft LE, Gallipoli P,
Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D,
Holyoake TL and Michie AM: CML cells actively evade host immune
surveillance through cytokine-mediated downregulation of MHC-II
expression. Blood. 129:199–208. 2017.
|
|
110
|
McCaw TR, Li M, Starenki D, Cooper SJ, Liu
M, Meza-Perez S, Arend RC, Buchsbaum DJ, Forero A and Randall TD:
The expression of MHC class II molecules on murine breast tumors
delays T-cell exhaustion, expands the T-cell repertoire, and slows
tumor growth. Cancer Immunol Immunother. 68:175–188. 2019.
|
|
111
|
Halder T, Pawelec G, Kirkin AF, Zeuthen J,
Meyer HE, Kun L and Kalbacher H: Isolation of novel HLA-DR
restricted potential tumor-associated antigens from the melanoma
cell line FM3. Cancer Res. 57:3238–3244. 1997.
|
|
112
|
Liu L, Wang L, Zhao L, He C and Wang G:
The Role of HLA-G in tumor escape: Manipulating the phenotype and
function of immune cells. Front Oncol. 10:5974682020.
|
|
113
|
Curigliano G, Criscitiello C, Gelao L and
Goldhirsch A: Molecular pathways: Human leukocyte antigen G
(HLA-G). Clin Cancer Res. 19:5564–5571. 2013.
|
|
114
|
Salomé B, Sfakianos JP, Ranti D, Daza J,
Bieber C, Charap A, Hammer C, Banchereau R, Farkas AM, Ruan DF, et
al: NKG2A and HLA-E define an alternative immune checkpoint axis in
bladder cancer. Cancer Cell. 40:1027–1043.e9. 2022.
|
|
115
|
Maeda A, Kawamura T, Ueno T, Usui N,
Eguchi H and Miyagawa S: The suppression of inflammatory
macro-phage-mediated cytotoxicity and proinflammatory cytokine
production by transgenic expression of HLA-E. Transpl Immunol.
29:76–81. 2013.
|
|
116
|
Chua HL, Serov Y and Brahmi Z: Regulation
of FasL expression in natural killer cells. Hum Immunol.
65:317–327. 2004.
|
|
117
|
Chen X, Lin Y, Yue S, Yang Y, Wang X, Pan
Z, Yang X, Gao L, Zhou J, Li Z, et al: Differential expression of
inhibitory receptor NKG2A distinguishes disease-specific exhausted
CD8+ T cells. MedComm. 2020:3e1112022.
|
|
118
|
Schumacher T, Bunse L, Pusch S, Sahm F,
Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, et al: A
vaccine targeting mutant IDH1 induces antitumour immunity. Nature.
512:324–327. 2014.
|
|
119
|
Li Y, Jiang W and Mellins ED: TCR-like
antibodies targeting autoantigen-mhc complexes: A mini-review.
Front Immunol. 13:9684322022.
|
|
120
|
Schachner LF, Phung W, Han G, Darwish M,
Bell A, Mellors JS, Srzentic K, Huguet R, Blanchette C and Sandoval
W: High-Throughput, quantitative analysis of peptide-exchanged MHCI
Complexes by native mass spectrometry. Anal Chem. 94:14593–14602.
2022.
|
|
121
|
Pourchet A, Fuhrmann SR, Pilones KA,
Demaria S, Frey AB, Mulvey M and Mohr I: CD8(+) T-cell immune
evasion enables oncolytic virus immunotherapy. EBioMedicine.
5:59–67. 2016.
|
|
122
|
Fischer C, Munks MW, Hill AB, Kroczek RA,
Bissinger S, Brand V, Schmittnaegel M, Imhof-Jung S, Hoffmann E,
Herting F, et al: Vaccine-induced CD8 T cells are redirected with
peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor
cells in vivo. MAbs. 12:18348182020.
|
|
123
|
Eshkiki ZS, Agah S, Tabaeian SP, Sedaghat
M, Dana F, Talebi A and Akbari A: Neoantigens and their clinical
applications in human gastrointestinal cancers. World J Surg Oncol.
20:3212022.
|
|
124
|
Duperret EK, Perales-Puchalt A, Stoltz R,
G H H, Mandloi N, Barlow J, Chaudhuri A, Sardesai NY and Weiner DB:
A Synthetic DNA, multi-neoantigen vaccine drives predominately MHC
Class I CD8+ T-cell responses, impacting tumor challenge. Cancer
Immunol Res. 7:174–182. 2019.
|
|
125
|
Tran E: Neoantigen-Specific T cells in
adoptive cell therapy. Cancer J. 28:278–284. 2022.
|
|
126
|
Alspach E, Lussier DM, Miceli AP,
Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E,
Vomund AN, et al: MHC-II neoantigens shape tumour immunity and
response to immunotherapy. Nature. 574:696–701. 2019.
|
|
127
|
Marty Pyke R, Thompson WK, Salem RM,
Font-Burgada J, Zanetti M and Carter H: Evolutionary Pressure
against MHC Class II binding cancer mutations. Cell.
175:416–428.e13. 2018.
|
|
128
|
Robbins PF: Tumor-Infiltrating lymphocyte
therapy and neoantigens. Cancer J. 23:138–143. 2017.
|
|
129
|
Jiang S, Geng S, Luo X, Zhang C, Yu Y,
Cheng M, Zhang S, Shi N and Dong M: Biomarkers of related driver
genes predict anti-tumor efficacy of immune checkpoint inhibitors.
Front Immunol. 13:9957852022.
|
|
130
|
Huang X, Zhang X, Bai X and Liang T:
Eating self for not be eaten: Pancreatic cancer suppresses
self-immunogenicity by autophagy-mediated MHC-I degradation. Signal
Transduct Target Ther. 5:942020.
|
|
131
|
Münz C: Canonical and non-canonical
functions of the autophagy machinery in MHC restricted antigen
presentation. Front Immunol. 13:8688882022.
|
|
132
|
Friedman LA, Bullock TN, Sloan EA, Ring KL
and Mills AM: MHC class I loss in endometrial carcinoma: A
potential resistance mechanism to immune checkpoint inhibition. Mod
Pathol. 34:627–636. 2021.
|
|
133
|
Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C,
Yin W, Yao J, Hang Q, Wu W, Zhang J, et al: Glucocorticoid receptor
regulates PD-L1 and MHC-I in pancreatic cancer cells to promote
immune evasion and immunotherapy resistance. Nat Commun.
12:70412021.
|
|
134
|
Westrich JA, Vermeer DW, Silva A, Bonney
S, Berger JN, Cicchini L, Greer RO, Song JI, Raben D, Slansky JE,
et al: CXCL14 suppresses human papillomavirus-associated head and
neck cancer through antigen-specific CD8+ T-cell responses by
upregulating MHC-I expression. Oncogene. 38:7166–7180. 2019.
|
|
135
|
Zheng X, Sun Y, Li Y, Ma J, Lv Y, Hu Y,
Zhou Y and Zhang J: A novel tongue squamous cell carcinoma cell
line escapes from immune recognition due to genetic alterations in
HLA Class I Complex. Cells. 12:352022.
|
|
136
|
Aparicio B, Repáraz D, Ruiz M, Llopiz D,
Silva L, Vercher E, Theunissen P, Tamayo I, Smerdou C, Igea A, et
al: Identification of HLA class I-restricted immunogenic
neoantigens in triple negative breast cancer. Front Immunol.
13:9858862022.
|
|
137
|
Gorris MAJ, van der Woude LL, Kroeze LI,
Bol K, Verrijp K, Amir AL, Meek J, Textor J, Figdor CG and de Vries
IJM: Paired primary and metastatic lesions of patients with
ipilimumab-treated melanoma: High variation in lymphocyte
infiltration and HLA-ABC expression whereas tumor mutational load
is similar and correlates with clinical outcome. J Immunother
Cancer. 10:e0043292022.
|
